Reproxalap FDA Approval Status
FDA Approved: No
Generic name: reproxalap
Company: Aldeyra Therapeutics, Inc.
Treatment for: Dry Eye Disease
Reproxalap is a first-in-class small-molecule modulator of RASP (reactive aldehyde species) in development for the treatment of signs and symptoms of dry eye disease.
- Dry eye disease is a common inflammatory disease characterized by insufficient moisture and lubrication in the anterior surface of the eye. In patients with dry eye disease, RASP may contribute to ocular inflammation, diminished tear production, ocular redness, and changes in tear lipid composition.
- Reproxalap works by inhibiting RASP to reduce ocular inflammation in dry eye disease.
Development timeline for reproxalap
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
